

# Luwy K Musey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/231678/publications.pdf>

Version: 2024-02-01

26  
papers

714  
citations

687363  
13  
h-index

552781  
26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

688  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 530-539.	3.3	80
2	Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. <i>Vaccine</i> , 2014, 32, 2399-2405.	3.8	79
3	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. <i>Vaccine</i> , 2018, 36, 6883-6891.	3.8	79
4	Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. <i>Vaccine</i> , 2015, 33, 2793-2799.	3.8	55
5	Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects. <i>Journal of Infectious Diseases</i> , 2019, 220, 411-419.	4.0	48
6	A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 763-770.	2.0	41
7	A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). <i>Vaccine</i> , 2022, 40, 162-172.	3.8	40
8	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. <i>Vaccine</i> , 2018, 36, 6875-6882.	3.8	35
9	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 540-548.	3.3	35
10	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Review of Vaccines</i> , 2021, 20, 243-256.	4.4	33
11	A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	32
12	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). <i>Vaccine</i> , 2021, 39, 6422-6436.	3.8	25
13	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. <i>Aids</i> , 2022, 36, 373-382.	2.2	15
14	Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2142-2147.	3.3	14
15	Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. <i>Vaccine</i> , 2016, 34, 3875-3881.	3.8	12
16	Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 70-77.	2.0	10
17	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Review of Vaccines</i> , 2021, 20, 257-267.	4.4	10
18	Sequential administration of Prevnar 13® and PNEUMOVAX® 23 in healthy participants 50 years of age and older. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2678-2690.	3.3	10

#	ARTICLE	IF	CITATIONS
19	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU). <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-14.	3.3	10
20	Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1931-1938.	3.3	9
21	Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. <i>Vaccine</i> , 2021, 39, 4231-4237.	3.8	9
22	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab605.	0.9	9
23	Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine. <i>Journal of Infectious Diseases</i> , 2021, 223, 2001-2012.	4.0	7
24	Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. <i>Expert Review of Vaccines</i> , 2022, 21, 115-123.	4.4	7
25	Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2135-2141.	3.3	5
26	Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE). <i>Vaccine</i> , 2022, 40, 1342-1351.	3.8	5